Systeemfibroosi

Systeemfibroosi, also known as systemic sclerosis or scleroderma, is a chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues. The exact cause of systemfibroosi is unknown, but it is believed to involve a combination of genetic predisposition and environmental triggers. The immune system mistakenly attacks the body's own tissues, leading to inflammation and the excessive production of collagen, a protein that provides structure to the skin and organs.

The disease can manifest in various ways, affecting different parts of the body. There are two main forms: localized scleroderma, which affects only the skin, and systemic sclerosis, which can involve internal organs such as the lungs, heart, kidneys, and gastrointestinal tract. Symptoms can range from mild skin thickening and discoloration to severe organ damage. Common symptoms include Raynaud's phenomenon, where fingers and toes become numb and cold in response to cold or stress, skin thickening, joint pain, and fatigue.

Diagnosis of systemfibroosi typically involves a physical examination, medical history, and specific tests such as blood tests to detect autoantibodies, and imaging studies to assess organ involvement. There is currently no cure for systemfibroosi, but treatments focus on managing symptoms, slowing disease progression, and improving quality of life. Therapies may include medications to reduce inflammation, immunosuppressants, drugs to manage specific organ complications, and physical therapy to maintain mobility. Early diagnosis and comprehensive management are crucial for individuals affected by this complex condition.